Adelaide, March 15, 2020: (ACN Newswire) – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.
As the only FDA-inspected lab of its type in the region, Agilex is located in Adelaide, South Australia, in a science and biotech specialist hub.
The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine / biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)
Agilex Biolabs CEO Jason Valentine said they will now be offering virtual tours of the lab for customers who have travel restrictions during the current Covid-19 outbreak.
CEO Jason Valentine said:
“Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma / biotechs from US, Europe and APAC.
“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.
“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”
Corporate Comm India(CCI Newswire)
